Back to search

Article

Selective Immune Silencing by Targeted TGF-β Agonists

2026-01-20

Abstract excerpt

Depletion of pathogenic T and B cells is a pillar of first-line therapies for inflammatory, autoimmune, and transplantation-related immunological diseases. However, concerns about adverse events, safety in immunocompromised patients, and disease relapse from incomplete depletion, limit clinical utility. Here, we exploit the immunosuppressive properties of Transforming growth factor beta (TGF-β), through selective...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
036029b9-9aeb-5a09-8751-c9d5780bed42
DOI
10.64898/2026.01.19.700410
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Selective Immune Silencing by Targeted TGF-β AgonistsDOI 10.64898/2026.01.19.700410
Select a neighboring publication to make it the new centre.